Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 11/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | RORC | P51449 | 9/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13093149 | 0.91 | BDKRB2 (0.88) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL1563792 | 0.90 | BDKRB2 (0.87) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL13146138 | 0.90 | BDKRB2 (0.78) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL14038629 | 0.90 | BDKRB2 (0.86) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL13145945 | 0.89 | BDKRB2 (0.85) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL13146134 | 0.89 | BDKRB2 (0.78) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL29572401 | 0.89 | BDKRB2 (1.00) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL1564049 | 0.89 | BDKRB2 (1.00) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL13146103 | 0.88 | BDKRB2 (0.88) | BDKRB2CYP3A4CYP2C19RORC | |
| SCHEMBL13092927 | 0.88 | BDKRB2 (0.76) | BDKRB2CYP3A4CYP2C19RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410134-B2 | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410134-B2 | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2008116620-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | BDKRB2, BDKRB1, HRH2 | BDKRB2 1/4885CYP3A4 762/4885CYP2C19 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.